L'Aquila, Italy

Francesco Galimi

This inventor holds 1 USPTO granted patent. Top assignee: Dompe S.p.a.. Active years: 2000.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Francesco Galimi. Retrieved from https://idiyas.com/inventor/francesco-galimi-4hlvyvo2

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2000

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Francesco Galimi: Innovator in Neurotherapeutics

Introduction

Francesco Galimi is a notable inventor based in L'Aquila, Italy. He has made significant contributions to the field of neurotherapeutics, particularly through his innovative research and development of medical treatments.

Latest Patents

Francesco Galimi holds a patent for a Macrophage Stimulating Protein (MSP) aimed at treating pathologies of the central and peripheral nervous system. This invention focuses on the use of MSP for preparing a medicament to address conditions of traumatic, infectious, or inflammatory origin.

Career Highlights

Galimi is associated with Dompe S.p.a., a company known for its commitment to advancing healthcare solutions. His work has been instrumental in developing therapies that target complex neurological conditions.

Collaborations

He has collaborated with esteemed colleagues such as Paolo Comoglio and Alessandro Vercelli, contributing to a dynamic research environment that fosters innovation.

Conclusion

Francesco Galimi's work exemplifies the intersection of scientific research and practical application in medicine. His contributions continue to pave the way for advancements in the treatment of neurological disorders.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…